The Ability of Preoperative Serum CA-125 to Predict Optimal Primary Tumor Cytoreduction in Stage III Epithelial Ovarian Carcinoma

By Chi D.S.   Venkatraman E.S.   Masson V.   Hoskins W.J.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 227-231

Elsevier

Access to resources Recommend Favorite

Preoperative Prediction of Optimal Resectability in Advanced Ovarian Cancer Using CA-125

By Berek J.S.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 225-226

Elsevier

Access to resources Recommend Favorite

Effect of Topotecan on Serum CA-125 in Patients with Advanced Epithelial Ovarian Cancer

By Nielsen H.A.   Nielsen D.   Engelholm S.A.  

Gynecologic Oncology, Vol. 77, Iss. 3, 2000-06 ,pp. : 383-388

Elsevier

Access to resources Recommend Favorite

The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer

By Deng X.   Hogdall E.V.S.   Hogdall C.K.   Norgaard-Pedersen B.   Jorgensen M.   Nielsen H.   Engelholm S.A.A.  

Gynecologic Oncology, Vol. 79, Iss. 3, 2000-12 ,pp. : 416-419

Elsevier

Access to resources Recommend Favorite

Preoperative CA-125 Levels in Patients with Hereditary Compared to Sporadic Epithelial Ovarian Carcinoma

By Leitao M.   Boyd J.  

Gynecologic Oncology, Vol. 84, Iss. 3, 2002-03 ,pp. : 413-415

Elsevier

Access to resources Recommend Favorite